The research was conducted by the Seattle-based University of Washington, with grant support from the Irish pharmaceutical company Mallinckrodt Pharmaceuticals. OFIRMEV was developed by Mallinckrodt Pharmaceuticals.
Here’s what you need to know:
1. The researchers analyzed almost 500,000 orthopedic surgery patients who received inpatient care. They compared the outcomes of those who received OFIRMEV and opioids for their pain management to those who solely received opioids for their pain management.
2. The average length of stay for patients who received OFIRMEV and opioids was 3.2 days. The average length of stay for patients who received opioids alone was 3.9 days.
3. The average hospitalization cost for patients who received OFIRMEV and opioids was $19,025. The average hospitalization costs for patient who received opioids alone was $19,928.
4. These findings suggest that providing orthopedic surgery patients with OFIRMEV in conjunction with other analgesics may reduce costs for hospitals and healthcare systems.
More articles on orthopedics:
University of Michigan awarded $3.9M NIH grant for musculoskeletal research: 4 notes
Hip, knee arthroplasty rates to explode through 2030: 5 study insights
Dr. Christopher Tveter joins New England Baptist Hospital: 3 things to know
